Small cell lung carcinoma:Tackling a resistant cancer AIM Biotech’s organ-on-a-chip has again demonstrated again how its technology allows the simulation of a tumor to study the migration of T cells in a human tumor environment. Mahadevan and coll. studied a...
Our applications development manager Lim Sei Hien discusses one recent study in cancer immunotherapy that benefited from the humanized technology in AIM Biotech’s organ-on-a-chip.
The blood-brain barrier is notoriously difficult to model in the lab—until now. AIM's proven technology and world-class contract research lab can get you better BBB data faster with our human-on-a-chip in vitro models.
AIM Biotech co-founder Roger Kamm, PhD gives a sneak peek into his opening keynote at next week's free workshop about M-CELS. Read on to see his personal insights as a leader in this growing field.
A free workshop this June about M-CELS will feature AIM Biotech co-founder Roger Kamm, PhD. As a keynote speaker, he’ll discuss his perspectives as a pioneering researcher at MIT.